Advanced Accelerator Applications: Clinical Trials

3 trials sponsored by Advanced Accelerator Applications, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Active not recruiting 1

Follow Advanced Accelerator Applications: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3Active not recruitingAdvanced Accelerator Applications2262020-01-082026-01-21
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate - Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Phase 3CompletedAdvanced Accelerator Applications2312012-09-062022-04-04
Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison
Rubidium-82, Sestamibi. reconstitution with sodium pertechnetate (99mTc) - Coronary Artery Disease
Phase 3CompletedAdvanced Accelerator Applications1352011-02-012014-05-14

Conditions studied

Coronary Artery Disease (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)  ·  Neuroendocrine Tumors (1)

Interventions

Octreotide (2)  ·  lutetium Lu 177 dotatate (2)  ·  Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1)  ·  Rubidium-82 (1)  ·  Sodium Pertechnetate Tc 99m (1)  ·  pasireotide (1)

Countries

United Kingdom (3)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  United States (2)  ·  Belgium (1)  ·  Canada (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  South Korea (1)

Top investigators

Leon Menezes, Dr. (1)

Results publications

PMID 28076709, PMID 29878866, PMID 32123969, PMID 33973550, PMID 34793718, PMID 38851203, PMID 39570708, PMID 40473457, PMID 42604001

NIH funding

2009 (1), 2023 (1)